Synthetic oligonucleotides as therapeutics: the coming of age.
Synthetic oligonucleotides (ODNs) are short nucleic acid chains that can act in a sequence specific manner to control gene expression. Significant progress has been made in the development of synthetic ODN therapeutics since the first demonstration of gene inhibition by antisense ODNs in a cell culture system two decades ago. This new class of therapeutic agents can potentially target any abnormally expressed genes in a broad range of diseases from viral infections to psychoneurological disorders. A number of "first" generation synthetic ODNs have entered into human clinical trials in the last few years. The eminent approval of the first ODN for the treatment of cytomaglovirus retinitis by the FDA in USA will provide much excitement that this new class of compounds holds great promise as a therapeutic "magic bullet". However, many obstacles still exist in the development of this technology. In this review, the current status of synthetic ODN chemistry, drug delivery methods, mechanisms of ODN action, potential clinical applications and its limitations in a wide range of human disorders will be described.
Ma
D D
DD
Department of Haematology, St Vincents Hospital, Sydney, New South Wales, Australia.
Rede
T
T
Naqvi
N A
NA
Cook
P D
PD
D000818:Animals; D001682:Biological Availability; D002318:Cardiovascular Diseases / Q000188:drug therapy; D030342:Genetic Diseases, Inborn / Q000188:drug therapy; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D008288:Malaria / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy; D009422:Nervous System Diseases / Q000188:drug therapy; D009841:Oligonucleotides / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D016376:Oligonucleotides, Antisense / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D014018:Tissue Distribution; D014777:Virus Diseases / Q000188:drug therapy
D009841:Oligonucleotides; D016376:Oligonucleotides, Antisense